Pediatric Medications and the Development of REMS

David M. Crowther, Pharm.D.


Pediatr Pharm. 2011;17(2) 

In This Article

Abstract and Introduction


Mitigating drug-associated patient risk is a significant concern not only for healthcare providers but also the Food and Drug Administration (FDA). This is apparent not only by the increasing numbers of strategic drug safety programs but also by their ever increasing complexity. As the area of risk mitigation continues to grow, it is important to understand how healthcare has arrived at its current state.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.